A family office based in Australia focuses on late stage therapeutics and medical devices that are past pre-clinical trials. Currently manages a $2.5 billion evergreen fund, and typically invests between $1 and $10 million. The firm normally makes co-investments in the USA, Europe, Israel, and Australia.
The firm is currently looking for new investment opportunities in therapeutics and PMA medical devices. The firm is only interested in later stage technology at Phase II or later, and is particularly interested in peripheral blood-based colorectal cancer diagnostics. The firm is open to all subsectors and indications in therapeutics and medical devices, though is not interested in software-enabled devices or lab equipment and drug development enabling technology. The firm does not invest in pre-clinical products, and only seeks products that are either in clinical trials (Phase II or later) with human data or on-the-market.
The firm seeks companies with an established management team with experience in the field. The firm does not typically take a board seat after an investment. The firm seeks distribution rights for Australia and Southeast Asia from international companies.
If you are interested in more information about this investor and other investors tracked by LSN, please email firstname.lastname@example.org